Streetbeat News

Analyst Ratings

MLTX

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on MoonLake (NASDAQ:MLTX).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:18 pm

KURA

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Kura Oncology (NASDAQ:KURA).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:17 pm

KALV

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on KalVista Pharma (NASDAQ:KALV).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:16 pm

VZ

Investors are showing a bullish stance on Verizon Communications (NYSE:VZ) with significant options activity. Benzinga's options scanner identified 8 uncommon trades, with a sentiment split of 62% bullish and 37% bearish. The price range focus is between $38.0 and $46.0. Verizon's stock is currently up 3.0% at $42.38, with analysts setting an average price target of $43.0.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:15 pm

PG

Deep-pocketed investors are showing a bearish sentiment towards Procter & Gamble (NYSE:PG) through options trading, with 58% of the activity being bearish. The trading activity suggests a focus on a price range between $165 and $185. Despite this, an analyst from DZ Bank has upgraded PG to a 'Buy' with a target price of $190.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:15 pm

NUE

Nucor's stock is experiencing an upward trend following JP Morgan's upgrade from Neutral to Overweight, with a price target increase from $170 to $174.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:13 pm

JSPR

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Jasper Therapeutics (NASDAQ:JSPR).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:12 pm

INSM

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Insmed (NASDAQ:INSM).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:10 pm

INCY

Cantor Fitzgerald analyst Eric Schmidt has reiterated a Neutral rating on Incyte (NASDAQ:INCY).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:09 pm

IMVT

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Immunovant (NASDAQ:IMVT).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:06 pm